New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

The US regulator has accepted Cytokinetics' marketing application for the cardiac myosin inhibitor, setting a target action date of 26th September 2025 to complete its review and, according to the ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...

BMS builds case ahead of FDA verdict The disappointing run of data with omecamtiv is in contrast to that of Bristol-Myers Squibb with its cardiac myosin inhibitor mavacamten. That drug is also ...

Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset aficamten. Read more here.

Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at https://www.cytokinetics.com. The webcast replay will be ...